Inferior vena cava

CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Retrieved on: 
Wednesday, April 24, 2024
Online, Science Publishing Group, Fontan procedure, Patient, Cell, Hepatocyte, Liver disease, Inferior vena cava, Science Translational Medicine, Hope, NIH, Hospital, Blood, Tissue, Robert, CHOP, Agent handling, Heart, Wellness, MD, RNA, Medical laboratory, Doctor of Philosophy, SVRF, Activity, Survivor, Disease, Pathology, Ventricular septal defect, Fibrosis, Stasi, FC, Assistant, Biology, Children's Hospital of Philadelphia, Quality of life, Scar, Defense, Pharmaceutical industry

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).

Key Points: 
  • In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
  • The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
  • As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
  • Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.

Legal-Bay Pre-Settlement Funding Reports Johnson & Johnson Talc Powder Settlement Delayed Yet Again

Retrieved on: 
Wednesday, April 3, 2024
Ovarian cancer, Health, News, Starch, J&J, Science, Johnson & Johnson, Inferior vena cava, Talc

NEW BRUNSWICK, N.J., April 3, 2024 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that Johnson & Johnson has just scored a win in their efforts to delay and/or outright avoid payouts on the 60,000+ lawsuits they are facing. A federal judge has just ruled that J&J will be given a new chance to argue the scientific evidence previously put forth that has shown a link between usage of their talcum powder and ovarian cancer.

Key Points: 
  • However, several studies dating back to the 1970s have already concluded that talc particles increase a person's chances of developing serious medical issues.
  • To apply for a cash advance lawsuit loan from your anticipated Johnson & Johnson talc baby powder lawsuit settlement, please visit the company's website HERE or call 877.571.0405.
  • They are one of the best lawsuit loan companies when it comes to mass tort litigations, and is currently the #1 talc funding company in the loan settlement industry.
  • Legal-Bay's loan for settlement funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

FIRE1 Completes Enrollment in U.S. Early Feasibility Study of Innovative Remote Heart Failure Monitoring System

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Surgery, Health Technology, Clinical Trials, Cardiology, Division, Hypervolemia, Surgeon, Rochester General Hospital, Ohio State University, Weill Cornell Medicine, Hospital, Duke University Hospital, Inferior vena cava, Heart failure, Patient, Medicine, IVC, Ageing, Physician, Pressure, Medical imaging

Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.

Key Points: 
  • Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.
  • The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.
  • FIRE1 seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a consumer-friendly device at home, similar to how continuous glucose monitoring transformed diabetes care.
  • “It is gratifying to see the physician interest in our novel technology that earlier studies suggest should be a more sensitive measure than pressure in monitoring heart failure,” said FIRE1 CEO and President Conor Hanley.

Legal-Bay Pre-Settlement Funding Reports Johnson & Johnson Talc Powder Settlement of $700MM with 40 States Nationwide

Retrieved on: 
Monday, January 22, 2024
Hail Mary, Health, Injury, Cancer, Fraud, Inferior vena cava, Talc, Mesothelioma, Johnson & Johnson, Bankruptcy, Ovarian cancer, Starch, Personal injury, Asbestos, Public opinion, J&J, Insurance

TRENTON, N.J., Jan. 22, 2024 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that Johnson & Johnson has agreed to a $700MM settlement with various state regulators across the country.  J&J has agreed to over $300MM above the $400MM that the company had reserved for this particular case. This first major settlement comes in conjunction with a dispute with its own shareholders, including a large fund in San Diego that determined J&J's concealment is tantamount to securities fraud – an opinion which a New Jersey Judge recently certified.

Key Points: 
  • TRENTON, N.J., Jan. 22, 2024 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that Johnson & Johnson has agreed to a $700MM settlement with various state regulators across the country.
  • J&J attempted a bankruptcy filing and a $9 billion offering to resolve that litigation, but the amount was rejected as unlawful.
  • The proposal by J&J would essentially provide the average settlement amount of each talc case to be approximately $150K per—a figure woefully short considering the severity of the victims' injuries.
  • Their loan for settlement funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

Inteleos Unveils Two New Point-of-Care Ultrasound Certifications

Retrieved on: 
Tuesday, September 26, 2023
IVC, European Information Technologies Certification Academy, Critical care, Arm, Education, DVT, Venae cavae, Inferior vena cava, Lung, Certification, POCUS, PCA, AAA, Health, Abdominal trauma, Abdominal aortic aneurysm, Nursing

ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, through its Point-of-Care Ultrasound (POCUS) Certification Academy (PCA), today announced the launch of an Inferior Vena Cava (IVC) certification and a Critical Care Specialty certification.

Key Points: 
  • ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, through its Point-of-Care Ultrasound (POCUS) Certification Academy (PCA), today announced the launch of an Inferior Vena Cava (IVC) certification and a Critical Care Specialty certification.
  • The PCA provides certification and educational resources for clinicians and is dedicated to ensuring quality patient care globally by upholding ultrasound standards with independently validated certifications.
  • The IVC Clinical Certificate and the Critical Care Specialty Certification include case-based assessments that simulate real-life clinical encounters and peer evaluations that determine practical skills and the user’s ability to interpret and diagnose findings.
  • “POCUS is not just an imaging tool, it's a compassionate touchpoint in patient care and a revolution in healthcare.

Teleflex Selected to Exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at Vizient Innovative Technology Exchange

Retrieved on: 
Friday, September 15, 2023
Teleflex, Inferior vena cava, Massachusetts Innovation & Technology Exchange, Anatomy, Catheter, PICC, TFX, Exchange, VPS, Navigation, Vizient, Inc., SVC, NYSE, Safety, Pharmaceutical industry, Nursing, Medical device, Medical imaging

WAYNE, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been selected to exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at the Vizient Innovative Technology Exchange.

Key Points: 
  • WAYNE, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been selected to exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at the Vizient Innovative Technology Exchange.
  • Vizient, Inc ., the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas.
  • The VPS Rhythm™ DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.
  • This device works in concert with the Arrow™ PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies.

$3.3M Verdict Will Stand In Case Citing Bard's Defective IVC Blood Clot Filter

Retrieved on: 
Thursday, August 17, 2023
Circuit court, IVC, Heart, CT, Bard, Surgeon, Inferior vena cava, Accident, Marketing, Lawyer, Judgement, United States Court of Appeals for the Seventh Circuit, Patient, Health, Injury, Pharmaceutical industry, Appeal

MADISON, Wis., Aug. 17, 2023 /PRNewswire/ -- A three-judge panel of the U.S. Court of Appeals for the Seventh Circuit has ruled that a $3.3 million jury verdict against medical device company Bard will stand, denying the company's bid for a new trial in an IVC filter product defect case.

Key Points: 
  • Bard's appellate briefing requesting a new trial stemmed from an alleged discrepancy between an expert witness's pretrial testimony and later trial testimony.
  • We're pleased that this panel of judges affirmed both the jury's verdict in Ms. Johnson's case and the federal district court's final judgment on that verdict."
  • The plaintiff in this case received the IVC filter implant ahead of a surgical procedure on her legs.
  • Mr. Martin told jurors in various IVC filter defect cases that Bard's failure to warn about the products' design flaws made the company's IVC filters a "ticking time bomb."

Legal-Bay Pre-Settlement Funding to Add Mesothelioma Cases for Funding Along with Talc After Large $18MM Verdict

Retrieved on: 
Monday, July 31, 2023
Talc, Pressure, Justice minister, False Claims Act, Falls, History, Judgement, J&J, Patent, Inferior vena cava, Mesothelioma, Johnson & Johnson, Ovarian cancer, Personal injury, Bankruptcy, Injury, Insurance

TRENTON, N.J., July 31, 2023 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that they are now adding mesothelioma victims to their list of Johnson & Johnson talc plaintiffs. The pharmaceutical company just lost their most recent court case, resulting in a landmark $18 million verdict. Both J&J and plaintiffs/lawyers await the next steps in what has been a painfully slow process.

Key Points: 
  • The pharmaceutical company just lost their most recent court case, resulting in a landmark $18 million verdict.
  • While J&J has offered to settle the cases, the amount seems to be a fraction of what juries are awarding in both talc and mesothelioma verdicts of late."
  • Legal-Bay is also funding loans for lawsuits on Round Up cases, Essure, Juul e-Cigarettes, Hernia Mesh, IVC Filters, and Exactech hip and knee recall cases.
  • Their lawsuit loans funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

Pre-Settlement Funding Firm Expects Johnson & Johnson Talcum Based Baby Powder Cases to Settle By Year's End

Retrieved on: 
Friday, May 5, 2023
Justice minister, False Claims Act, Lawyer, Falls, Federal, History, Judgement, J&J, Patent, Inferior vena cava, Johnson & Johnson, Ovarian cancer, Personal injury, Bankruptcy, Cryptocurrency, Pharmaceutical industry, Tobacco, Insurance

NEW BRUNSWICK, N.J., May 5, 2023 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that they expect a global settlement to be reached in the landmark Johnson & Johnson Baby Powder Talc cases. It will be one of the largest mass tort settlements in U.S. history, costing J&J over $10 billion to resolve over 100,000 claims. 

Key Points: 
  • NEW BRUNSWICK, N.J., May 5, 2023 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that they expect a global settlement to be reached in the landmark Johnson & Johnson Baby Powder Talc cases.
  • It will be one of the largest mass tort settlements in U.S. history, costing J&J over $10 billion to resolve over 100,000 claims.
  • Legal-Bay is also funding Round Up cases, Essure, Juul e-Cigarettes, Hernia Mesh, IVC Filters, and Exactech hip and knee recall cases.
  • To apply, please visit the company's website HERE or call toll-free at: 877.571.0405 where agents are available to answer your questions.

Teleflex Launches New Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet in the United States

Retrieved on: 
Tuesday, May 2, 2023
BD1, Inferior vena cava, Anatomy, Catheter, TFX, Research, PICC, Hospital, VPS, SVC, NYSE, CHG, Medical device, Medical imaging, Teleflex

The new Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.

Key Points: 
  • The new Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.
  • The next-generation VPS Rhythm® DLX Device provides real-time catheter tip location information by using the patient’s cardiac electrical activity.
  • The device is also available with an optional integrated ultrasound featuring a Catheter-to-Vessel ratio tool that promotes standardization in vessel measurement.
  • This device works in concert with the Arrow® PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies.